Tentative nod for Dexcel omeprazole
This article was originally published in The Tan Sheet
Executive Summary
FDA has granted tentative approval for Dexcel Pharma Technologies' new drug application for its generic Prilosec OTC (omeprazole 20 mg), which could be held up by AstraZenca's patent litigation, Perrigo says June 20. Allegan, Mich.-based Perrigo has exclusive U.S. marketing and distribution rights for Dexcel's product. Perrigo says FDA's final approval of the generic Prilosec OTC will not come until the expiration of the 30-month period provided for AstraZeneca under the Hatch-Waxman Act, which would be November 2008. However, trial is expected to begin later this year in U.S. District Court for Delaware in the patent infringement suit AstraZeneca filed in May 2006 against Dexcel, alleging the Israel-based firm's application infringes on three patents: two expiring in October 2007 and one in May 2019. The litigation initiated the patent challenge process under Hatch-Waxman (1"The Tan Sheet" June 12, 2006, p. 5)...
You may also be interested in...
Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues
Perrigo has acquired marketing rights for a potential generic version of Prilosec OTC, but litigation against the firm's partner Dexcel Pharma by AstraZeneca could block generic OTC omeprazole through 2019
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.